Atea Pharmaceuticals Files 8-K for Financials
Ticker: AVIR · Form: 8-K · Filed: Mar 24, 2025 · CIK: 1593899
| Field | Detail |
|---|---|
| Company | Atea Pharmaceuticals, Inc. (AVIR) |
| Form Type | 8-K |
| Filed Date | Mar 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Atea Pharma filed an 8-K for financial statements and exhibits on 3/24.
AI Summary
Atea Pharmaceuticals, Inc. filed an 8-K on March 24, 2025, reporting events that occurred on March 21, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates routine corporate reporting, likely related to financial statements and exhibits, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any new material risks or significant corporate changes.
Key Players & Entities
- Atea Pharmaceuticals, Inc. (company) — Registrant
- March 24, 2025 (date) — Date of report
- March 21, 2025 (date) — Date of earliest event reported
- 225 Franklin Street, Suite 2100, Boston, MA 02110 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of March 21, 2025.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on March 24, 2025.
What is the earliest event date reported in this filing?
The earliest event date reported in this filing is March 21, 2025.
What is the principal executive office address for Atea Pharmaceuticals, Inc.?
The principal executive office address for Atea Pharmaceuticals, Inc. is 225 Franklin Street, Suite 2100, Boston, MA 02110.
Does this filing indicate any significant changes or material events beyond routine financial reporting?
Based on the provided text, the filing primarily concerns 'Financial Statements and Exhibits' and 'Other Events', suggesting routine corporate reporting rather than specific new material events.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 24, 2025 regarding Atea Pharmaceuticals, Inc. (AVIR).